scholarly journals Monoclonal gammopathy of undetermined significance is associated with prostate cancer in a population-based cohort study

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Nicola Hornung ◽  
Mirjam Frank ◽  
Nico Dragano ◽  
Jan Dürig ◽  
Ulrich Dührsen ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Risk Factors ◽  
Cohort Study ◽  
Monoclonal Gammopathy ◽  
Population Based ◽  
Effect Estimate ◽  
Supporting Evidence ◽  
Shared Risk ◽  
Incident Cases ◽  
Undetermined Significance

AbstractRegister-based studies indicate a possible association of monoclonal gammopathy of undetermined significance (MGUS) and prostate cancer (PCa). Aim of the present study was to investigate the relationship between MGUS and PCa considering potentially shared risk factors. Data from the prospective population-based Heinz Nixdorf Recall cohort study of 2.385 men (age 45–85) were analyzed. MGUS was determined at three points in time; cases of cancer were assessed annually. Potentially shared risk factors were assessed at baseline. Hazard ratios (HR), adjusted for age and educational attainment, and corresponding 95%-confidence intervals (95%-CI) were calculated. 157 cases of MGUS and 143 incident cases of PCa were detected. Of 19 participants diagnosed with both, MGUS and incident PCa, only in one case MGUS did not clearly occur before PCa. MGUS was associated with PCa presenting a HR of 2.00 (95%-CI: 1.23–3.25). Stratified by isotype, IgM-MGUS showed the strongest association with PCa. There was no relevant change of the effect estimate when adjusting for potentially shared risk factors. We were able to give supporting evidence for an association between MGUS and PCa and pointed out its temporality. There was no indication that the observed association is due to shared risk factors. The present study indicated that different isotypes of MGUS differ in the strength of the effect on PCa-risk. Based on these findings, future studies investigating the pathophysiological background of the association will be needed.

Untangling fracture risk in monoclonal gammopathy of undetermined significance: A population‐based cohort study

2021 ◽  
Author(s):  
Sæmundur Rögnvaldsson ◽  
Thor Aspelund ◽  
Sigrún Thorsteinsdóttir ◽  
Ingemar Turesson ◽  
Magnus Björkholm ◽  
...  
Keyword(s):  
Cohort Study ◽  
Fracture Risk ◽  
Monoclonal Gammopathy ◽  
Population Based ◽  
Undetermined Significance

scholarly journals Monoclonal gammopathy of undetermined significance and COVID-19: a population-based cohort study

2021 ◽  
Vol 11 (12) ◽  
Author(s):  
Saemundur Rognvaldsson ◽  
Elias Eythorsson ◽  
Sigrun Thorsteinsdottir ◽  
Brynjar Vidarsson ◽  
Pall Torfi Onundarson ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Cohort Study ◽  
Odds Ratio ◽  
Monoclonal Gammopathy ◽  
Large Population ◽  
Immune Dysfunction ◽  
Population Based ◽  
Study Group ◽  
Increased Risk ◽  
Undetermined Significance

AbstractMultiple myeloma (MM) patients have increased risk of severe coronavirus disease 2019 (COVID-19) when infected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Monoclonal gammopathy of undetermined significance (MGUS), the precursor of MM has been associated with immune dysfunction which may lead to severe COVID-19. No systematic data have been published on COVID-19 in individuals with MGUS. We conducted a large population-based cohort study evaluating the risk of SARS-CoV-2 infection and severe COVID-19 among individuals with MGUS. We included 75,422 Icelanders born before 1976, who had been screened for MGUS in the Iceland Screens Treats or Prevents Multiple Myeloma study (iStopMM). Data on SARS-CoV-2 testing and COVID-19 severity were acquired from the Icelandic COVID-19 Study Group. Using a test-negative study design, we included 32,047 iStopMM participants who had been tested for SARS-CoV-2, of whom 1754 had MGUS. Among these participants, 1100 participants, tested positive, 65 of whom had MGUS. Severe COVID-19 developed in 230 participants, including 16 with MGUS. MGUS was not associated with SARS-CoV-2 infection (Odds ratio (OR): 1.05; 95% confidence interval (CI): 0.81–1.36; p = 0.72) or severe COVID-19 (OR: 0.99; 95%CI: 0.52–1.91; p = 0.99). These findings indicate that MGUS does not affect the susceptibility to SARS-CoV-2 or the severity of COVID-19.

scholarly journals Obesity and the Transformation of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma: A Population-Based Cohort Study

2016 ◽  
Vol 109 (5) ◽  
pp. djw264 ◽  
Author(s):  
Su-Hsin Chang ◽  
Suhong Luo ◽  
Theodore S. Thomas ◽  
Katiuscia K. O’Brian ◽  
Graham A. Colditz ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Cohort Study ◽  
Monoclonal Gammopathy ◽  
Population Based ◽  
Undetermined Significance

Socioeconomic Position is Positively Associated with Monoclonal Gammopathy of Undetermined Significance in a Population-based Cohort Study

2019 ◽  
Vol 98 (12) ◽  
pp. 2761-2767
Author(s):  
Börge Schmidt ◽  
Elisabeth Debold ◽  
Mirjam Frank ◽  
Marina Arendt ◽  
Nico Dragano ◽  
...  
Keyword(s):  
Cohort Study ◽  
Socioeconomic Position ◽  
Monoclonal Gammopathy ◽  
Population Based ◽  
Undetermined Significance

scholarly journals Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study

The Lancet ◽  
2010 ◽  
Vol 375 (9727) ◽  
pp. 1721-1728 ◽  
Author(s):  
Angela Dispenzieri ◽  
Jerry A Katzmann ◽  
Robert A Kyle ◽  
Dirk R Larson ◽  
L Joseph Melton ◽  
...  
Keyword(s):  
Cohort Study ◽  
Light Chain ◽  
Monoclonal Gammopathy ◽  
Population Based ◽  
Risk Of Progression ◽  
Undetermined Significance

scholarly journals Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies

2021 ◽  
Vol 11 (5) ◽  
Author(s):  
Sæmundur Rögnvaldsson ◽  
Thorvardur Jon Love ◽  
Sigrun Thorsteinsdottir ◽  
Elín Ruth Reed ◽  
Jón Þórir Óskarsson ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Early Treatment ◽  
Monoclonal Gammopathy ◽  
Controlled Trial ◽  
Participation Rate ◽  
Population Based ◽  
Early Therapy ◽  
Screening Study ◽  
Undetermined Significance

AbstractMonoclonal gammopathy of undetermined significance (MGUS) precedes multiple myeloma (MM). Population-based screening for MGUS could identify candidates for early treatment in MM. Here we describe the Iceland Screens, Treats, or Prevents Multiple Myeloma study (iStopMM), the first population-based screening study for MGUS including a randomized trial of follow-up strategies. Icelandic residents born before 1976 were offered participation. Blood samples are collected alongside blood sampling in the Icelandic healthcare system. Participants with MGUS are randomized to three study arms. Arm 1 is not contacted, arm 2 follows current guidelines, and arm 3 follows a more intensive strategy. Participants who progress are offered early treatment. Samples are collected longitudinally from arms 2 and 3 for the study biobank. All participants repeatedly answer questionnaires on various exposures and outcomes including quality of life and psychiatric health. National registries on health are cross-linked to all participants. Of the 148,704 individuals in the target population, 80 759 (54.3%) provided informed consent for participation. With a very high participation rate, the data from the iStopMM study will answer important questions on MGUS, including potentials harms and benefits of screening. The study can lead to a paradigm shift in MM therapy towards screening and early therapy.

Sign in / Sign up

Export Citation Format

Share Document